Cargando…
Detecting cardiomyopathies in pregnancy and the postpartum period using ECG
BACKGROUND: Cardiovascular disease (CVD) has been identified as a major threat to maternal health in the US and UK with cardiomyopathy being one of the most common acquired CVD in the pregnant and postpartum period. Diagnosing cardiomyopathy in pregnancy is challenging due to an overlap of cardiovas...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708041/ http://dx.doi.org/10.1093/ehjdh/ztab104.3062 |
_version_ | 1784840834083979264 |
---|---|
author | Adedinsewo, D Johnson, P W Douglass, E J Attia, Z I Phillips, S D Goswami, R M Yamani, M H Connolly, H M Rose, C H Sharpe, E E Lopez-Jimenez, F Friedman, P A Carter, R E Noseworthy, P A |
author_facet | Adedinsewo, D Johnson, P W Douglass, E J Attia, Z I Phillips, S D Goswami, R M Yamani, M H Connolly, H M Rose, C H Sharpe, E E Lopez-Jimenez, F Friedman, P A Carter, R E Noseworthy, P A |
author_sort | Adedinsewo, D |
collection | PubMed |
description | BACKGROUND: Cardiovascular disease (CVD) has been identified as a major threat to maternal health in the US and UK with cardiomyopathy being one of the most common acquired CVD in the pregnant and postpartum period. Diagnosing cardiomyopathy in pregnancy is challenging due to an overlap of cardiovascular symptoms with normal pregnancy symptoms. PURPOSE: The purpose of this study was to evaluate the effectiveness of an ECG based deep learning model in identifying cardiomyopathy among pregnant and postpartum women. METHODS: We utilized an ECG based deep learning model to detect cardiomyopathy in a cohort of pregnant or postpartum women seen at multiple hospital sites. Model performance was evaluated using area under the curve (AUC), accuracy, sensitivity, and specificity. We compared the diagnostic probabilities of the deep learning model with natriuretic peptides and a multivariable model consisting of demographic and clinical parameters. RESULTS: 1,807 women were included. 7%, 10% and 13% had LVEF ≤35%, <45% and <50% respectively. The ECG based deep learning model identified cardiomyopathy with an AUC of 0.92 for left ventricular ejection fraction (LVEF) ≤35%, 0.89 for LVEF <45% and 0.87 for LVEF <50%. For LVEF ≤35%, AUC was higher in Black (0.95) and Hispanic (0.98) women compared to white (0.91). Natriuretic peptides and the multivariable model had AUCs of 0.85 and 0.72 respectively. CONCLUSIONS: A deep learning model effectively identifies cardiomyopathy in pregnant or postpartum women, outperforms natriuretic peptides and traditional clinical parameters with the potential to become a powerful initial screening tool for cardiomyopathy in the obstetric care setting. FUNDING ACKNOWLEDGEMENT: Type of funding sources: Other. Main funding source(s): This study was made possible using resources supported by the Mayo Clinic Women's Health Research Center and the Mayo Clinic Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Program funded by the National Institutes of Health (NIH), grant number K12 HD065987. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
format | Online Article Text |
id | pubmed-9708041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97080412023-01-27 Detecting cardiomyopathies in pregnancy and the postpartum period using ECG Adedinsewo, D Johnson, P W Douglass, E J Attia, Z I Phillips, S D Goswami, R M Yamani, M H Connolly, H M Rose, C H Sharpe, E E Lopez-Jimenez, F Friedman, P A Carter, R E Noseworthy, P A Eur Heart J Digit Health Abstracts BACKGROUND: Cardiovascular disease (CVD) has been identified as a major threat to maternal health in the US and UK with cardiomyopathy being one of the most common acquired CVD in the pregnant and postpartum period. Diagnosing cardiomyopathy in pregnancy is challenging due to an overlap of cardiovascular symptoms with normal pregnancy symptoms. PURPOSE: The purpose of this study was to evaluate the effectiveness of an ECG based deep learning model in identifying cardiomyopathy among pregnant and postpartum women. METHODS: We utilized an ECG based deep learning model to detect cardiomyopathy in a cohort of pregnant or postpartum women seen at multiple hospital sites. Model performance was evaluated using area under the curve (AUC), accuracy, sensitivity, and specificity. We compared the diagnostic probabilities of the deep learning model with natriuretic peptides and a multivariable model consisting of demographic and clinical parameters. RESULTS: 1,807 women were included. 7%, 10% and 13% had LVEF ≤35%, <45% and <50% respectively. The ECG based deep learning model identified cardiomyopathy with an AUC of 0.92 for left ventricular ejection fraction (LVEF) ≤35%, 0.89 for LVEF <45% and 0.87 for LVEF <50%. For LVEF ≤35%, AUC was higher in Black (0.95) and Hispanic (0.98) women compared to white (0.91). Natriuretic peptides and the multivariable model had AUCs of 0.85 and 0.72 respectively. CONCLUSIONS: A deep learning model effectively identifies cardiomyopathy in pregnant or postpartum women, outperforms natriuretic peptides and traditional clinical parameters with the potential to become a powerful initial screening tool for cardiomyopathy in the obstetric care setting. FUNDING ACKNOWLEDGEMENT: Type of funding sources: Other. Main funding source(s): This study was made possible using resources supported by the Mayo Clinic Women's Health Research Center and the Mayo Clinic Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Program funded by the National Institutes of Health (NIH), grant number K12 HD065987. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Oxford University Press 2021-12-29 /pmc/articles/PMC9708041/ http://dx.doi.org/10.1093/ehjdh/ztab104.3062 Text en Reproduced from: European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.3062, https://doi.org/10.1093/eurheartj/ehab724.3062 by permission of Oxford University Press on behalf of the European Society of Cardiology. The opinions expressed in the Journal item reproduced as this reprint are those of the authors and contributors, and do not necessarily reflect those of the European Society of Cardiology, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The mention of trade names, commercial products or organizations, and the inclusion of advertisements in this reprint do not imply endorsement by the Journal, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in the Journal. The ultimate responsibility for the use and dosage of drugs mentioned in this reprint and in interpretation of published material lies with the medical practitioner, and the editors and publisher cannot accept liability for damages arising from any error or omissions in the Journal or in this reprint. Please inform the editors of any errors. © The Author(s) 2021. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Adedinsewo, D Johnson, P W Douglass, E J Attia, Z I Phillips, S D Goswami, R M Yamani, M H Connolly, H M Rose, C H Sharpe, E E Lopez-Jimenez, F Friedman, P A Carter, R E Noseworthy, P A Detecting cardiomyopathies in pregnancy and the postpartum period using ECG |
title | Detecting cardiomyopathies in pregnancy and the postpartum period using ECG |
title_full | Detecting cardiomyopathies in pregnancy and the postpartum period using ECG |
title_fullStr | Detecting cardiomyopathies in pregnancy and the postpartum period using ECG |
title_full_unstemmed | Detecting cardiomyopathies in pregnancy and the postpartum period using ECG |
title_short | Detecting cardiomyopathies in pregnancy and the postpartum period using ECG |
title_sort | detecting cardiomyopathies in pregnancy and the postpartum period using ecg |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708041/ http://dx.doi.org/10.1093/ehjdh/ztab104.3062 |
work_keys_str_mv | AT adedinsewod detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT johnsonpw detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT douglassej detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT attiazi detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT phillipssd detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT goswamirm detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT yamanimh detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT connollyhm detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT rosech detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT sharpeee detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT lopezjimenezf detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT friedmanpa detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT carterre detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg AT noseworthypa detectingcardiomyopathiesinpregnancyandthepostpartumperiodusingecg |